How India Exports Celecoxib to the World

In the United States, celecoxib is approved for the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The original New Drug Application (NDA) for Celebrex (celecoxib) was approved by the FDA on December 23, 1998. Subsequently, numerous Abbreviated New Drug Applications (ANDAs) have been approved, allowing for the marketing of generic versions. The FDA's Orange Book lists multiple approved ANDAs for celecoxib, indicating a competitive generic market. Notably, the high number of Indian exporters (326) underscores India's pivotal role in supplying generic celecoxib to the U.S. market.

Regarding import alerts, as of March 2026, there are no active FDA import alerts specifically targeting celecoxib products from India. However, manufacturers must adhere to the FDA's stringent Current Good Manufacturing Practice (CGMP) regulations to ensure product quality and safety. The regulatory pathway for generic celecoxib involves demonstrating bioequivalence to the reference listed drug, compliance with CGMP, and submission of an ANDA for FDA review and approval.

In the European Union, celecoxib is authorized for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The European Medicines Agency (EMA) granted marketing authorization for Onsenal (celecoxib) on October 17, 2003, specifically for the reduction of adenomatous intestinal polyps in familial adenomatous polyposis (FAP). However, this authorization was withdrawn on March 28, 2011, due to insufficient data confirming clinical benefit. The EMA concluded that the benefit of celecoxib in FAP patients had not been sufficiently demonstrated and did not outweigh the increased risk of cardiovascular and gastrointestinal side effects. (ema.europa.eu)

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the regulation of medicinal products. Following Brexit, the UK has established its own regulatory framework, though it closely aligns with EMA guidelines. Manufacturers exporting to the UK must comply with the MHRA's requirements, including obtaining marketing authorization and adhering to Good Manufacturing Practice (GMP) standards.

Celecoxib is included in the World Health Organization's (WHO) Model List of Essential Medicines, recognizing its importance in a basic health system. The WHO Model List serves as a guide for the development of national and institutional essential medicine lists. Regarding pharmacopoeial standards, celecoxib is monographed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). These monographs provide standardized specifications for the quality, purity, and strength of the drug, ensuring consistency across different markets.

In India, celecoxib is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines. As of March 2026, celecoxib is not listed under the DPCO's price control list, allowing manufacturers to set prices based on market dynamics. For exports, the Directorate General of Foreign Trade (DGFT) mandates that pharmaceutical products, including celecoxib, obtain a No Objection Certificate (NOC) to ensure compliance with export regulations and to prevent shortages in the domestic market.

The primary patents for celecoxib have expired, leading to a robust generic market with multiple manufacturers producing the drug. This expiration has facilitated increased competition, resulting in more affordable pricing and wider accessibility. The presence of 326 active Indian exporters highlights the competitive landscape and India's significant contribution to the global supply of generic celecoxib.

In June 2025, the FDA approved a new generic version of celecoxib, further intensifying market competition and potentially impacting pricing strategies for existing manufacturers.

In September 2025, the EMA updated its guidelines on the cardiovascular safety of NSAIDs, including celecoxib, emphasizing the need for ongoing pharmacovigilance and risk assessment.

In December 2025, the NPPA conducted a review of non-scheduled drug prices, including celecoxib, to monitor market trends and ensure fair pricing practices.

In February 2026, the WHO released a report highlighting the importance of maintaining quality standards in the manufacturing of essential medicines like celecoxib, urging member countries to strengthen regulatory oversight.

In March 2026, the DGFT introduced a streamlined process for obtaining export NOCs for pharmaceutical products, aiming to facilitate smoother export operations for manufacturers.

These developments underscore the dynamic nature of the pharmaceutical industry and the importance of staying abreast of regulatory changes to ensure compliance and market competitiveness.

India's pharmaceutical industry, including the production of Celecoxib, heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is significant, as China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply. Such reliance exposes the supply chain to vulnerabilities stemming from geopolitical tensions, trade disputes, and environmental regulations affecting Chinese manufacturing.

Recent disruptions have underscored these risks. In September 2025, China implemented aggressive pricing strategies, slashing the prices of 41 APIs and KSMs by 40–50%, aiming to undercut Indian manufacturers. Additionally, in February 2025, the FDA issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practices (cGMP), highlighting ongoing quality concerns. These events have led to supply chain disruptions and increased costs for Indian pharmaceutical companies.

The export market for Celecoxib from India is notably concentrated. The top five exporters—UMEDICA LABORATORIES PRIVATE LIMITED, MACLEODS PHARMACEUTICALS LTD, ALEMBIC PHARMACEUTICALS LIMITED, CIPLA LIMITED, and MICRO LABS LIMITED—account for 55.8% of total exports, with UMEDICA alone holding an 18.6% share. This concentration poses a risk, as disruptions affecting these key suppliers could significantly impact global supply.

To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in November 2024, aiming to boost domestic production of critical APIs and reduce import dependence. The scheme has led to the inauguration of two greenfield plants manufacturing essential molecules like Penicillin G and Clavulanic Acid. However, the effectiveness of this initiative in diversifying the supplier base for Celecoxib remains to be seen.

Geopolitical tensions have further strained the pharmaceutical supply chain. In February 2026, the closure of the Strait of Hormuz disrupted the supply of raw materials to Asia's petrochemical industry, leading to production cutbacks and force majeure declarations. Such disruptions can delay shipments of APIs and KSMs, increasing costs and affecting the timely delivery of pharmaceuticals like Celecoxib.

Additionally, escalating tensions between the U.S. and China have raised concerns about potential trade restrictions and tariffs, which could further complicate the import of essential raw materials. The FDA has been actively monitoring these developments to prevent and mitigate potential drug shortages.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source for APIs and KSMs.

• Enhance Domestic Production: Invest in local manufacturing capabilities for critical raw materials to decrease reliance on imports.

• Strengthen Quality Controls: Implement rigorous quality assurance protocols to address cGMP compliance issues and ensure product integrity.

• Monitor Geopolitical Developments: Establish a dedicated team to track international events that could impact the supply chain and develop contingency plans accordingly.

• Collaborate with Regulatory Bodies: Work closely with agencies like the FDA to stay informed about potential shortages and regulatory changes, ensuring proactive responses to emerging risks.

RISK_LEVEL: HIGH